newsfilter
← Earnings
Earnings Releases·

Wave Life Sciences — Third Quarter 2026 Earnings Summary

Wave Life Sciences reported a net loss of $61.9 million for the third quarter of 2026, with revenue reaching $13.2 million driven by its GSK collaboration. The company maintains a cash runway into the third quarter of 2028, holding $431.0 million in cash and marketable securities as of September 30, 2026. Clinically, Wave is advancing WVE-006 for alpha-1 antitrypsin deficiency with FDA alignment for a registrational trial, while WVE-007 for obesity continues dosing in Phase 2a monotherapy and combination studies. Additionally, the company plans to submit a clinical trial application for WVE-008 targeting PNPLA3 liver disease in the fourth quarter of 2026.

Company
WAVE LIFE SCIENCES INC
Sector
Healthcare
Industry
Biotechnology